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Phar acokinetics and Adverse Effects of Drugs
 
1. Introduction
This chapter aims to elaborate on the linkages between pharmacokinetics and the advent 
of adverse effects of drugs. It is well known that pharmacokinetics is about the journey of 
the drug in the body, from its absorption, through its distribution and metabolism, to its 
elimination from the body. During this journey, after its absorption and distribution, the drug 
reaches its specific sites where it interacts with its receptors, usually proteins and enzymes, 
and produces its biological effects; this is known as “pharmacodynamics.” The biological 
effects lead to clinical effects that are observed in patients; this is known as “therapeutics or 
pharmacotherapeutics.” In the following sections, the actions of the body on a drug and the 
actions of the drug on the body are reviewed in each stage to explain how adverse effects 
occur. In doing so, the mechanisms and risk factors of adverse effects will be addressed. The 
next section deals with the absorption, followed by the distribution and excretion of drugs as 
they relate to the occurrence of adverse effects. A final section will deal with risk factors before 
some concluding remarks are presented.
2. Rates of absorption influence on the occurrence of adverse effects
For the majority of drugs that are administered by other routes than intravenous injection, they 
need to overcome several hurdles before they reach the systemic circulation. These include the 
layers of the outer skin of the body or veins in case of subcutaneous and intramuscular routes 
or the walls of the digestive system. For drugs administered orally, the active substances must 
first be released from the dosage from, namely tablets, capsules, and other forms. There will 
be a reduction of therapeutic effects if there is little absorption, or destruction of the drug by 
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digestive system enzymes, or if the active substance was not released from its dosage form 
[1, 2]. Sometimes the absorption may be impaired by the presence of foods or other drugs or 
substances that react with the active substance and make it not absorbable. On the contrary, 
the presence of physical lesions in the digestive tract, or substances that increases the liposolu-
bility of the active substance may actually increase its absorption [3].
Several factors affect the journey of the drug that result in increased or decreased absorption 
or volume of distribution as well as the metabolism thereof. The physicochemical characteris-
tics of the drug itself, the pharmaceutical dosage form it is in and its intrinsic quality, the state 
of the first layers of skin or membranes through which the drug is to be absorbed through, the 
composition of the environment such as the presence or absence of foods or other chemicals 
in the digestive system as well as the type of foods or the other chemicals, the type and num-
ber of carriers subunits of enzymes or proteins complex available at the site of absorption, all 
influence the absorption rates [4].
For medicines administered orally, whether tablets, capsules, solution, suspension, syrup, 
or elixir, it should be noted that the gastrointestinal tract is a harsh environment. With its 
low pH, acid-labile drugs such as benzylpenicillin (penicillin G) and methicillin, they become 
inactivated as a result of the catalysis that takes place due to beta-lactamase enzymes [4–6]. 
Similarly, the presence of proteases makes the oral route unsuitable for many proteins and 
peptides such as insulin and oxytocin [1–3]. When taken orally, the absorption of drugs 
occurs chiefly by passive diffusion of lipophilic molecules and by carrier-mediated transport 
for drugs that are structurally similar to endogenous compounds such as levodopa and 5- 
fluorouracil. With passive diffusion, the rate of absorption is proportional to the concentra-
tion or the amount of drug to be absorbed and the fraction or percentage absorbed in a given 
interval remains constant.
With carrier-mediated mechanisms, be it active transport or facilitated diffusion, there is a lim-
ited capacity and the transporter can be saturated, hence limiting the amount of drug reach-
ing the systemic circulation. In this instance, increasing the dose will result in local adverse 
effects [6]. Clinicians ought to understand the particularity of a particular drug before decid-
ing to indiscriminately increase the dose when a subtherapeutic effect is observed. Indeed, 
this remark is true even for drugs absorbed by passive diffusion like aspirin (salicylic acid) as 
the percentage absorbed is independent of the continuous concentration but proportional to 
the initial drug concentration.
Nowadays, the proliferation of substandard and falsified drugs particularly in Africa makes 
it difficult to predict the beneficial effects of these drugs [7]. This is because the intrinsic phar-
maceutical quality of these drugs is not optimal leading to several consequences with regard 
to the absorption and elicited effects of these drugs. Several examples have been encountered 
in clinical practice; for instance, cotrimoxazole tablets badly compressed have been taken 
by patients just to be excreted intact in their feces! This example means that no dissolution 
took place, so little or nothing of the drug was absorbed, consequently, the therapeutic effects 
expected from the drug could not be elicited rather than the placebo effect.
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As depicted in Figure 1, largely unionized substances such as, aspirin when in acidic environ-
ment, it is absorbed from the stomach but most of the absorption occurs in the small intestine 
where the large surface area compensates for the less favorable degree of ionization. On the 
contrary, weak bases, which are highly ionized in gastric acid, cannot be absorbed until they 
have left the stomach, so delayed gastric emptying (when foods is in the stomach) can delay 
the effect of such drugs [6, 8].
On the other hand, it is often recommended that drugs should be taken at meal times. This 
is to aid adherence to treatment and in some circumstances, to reduce gastric irritation (a 
local adverse effect), as, for example, with aspirin, which may cause gastric bleeding. It is 
noted here that the effect of food is not always predictable, although, generally, food delays 
gastric emptying and increases the secretion of gastric acid while reducing the overall gastric 
pH. Hence, the presence of foods may reduce the absorption of drugs such as ketoconazole 
that are more soluble in acid; yet on the contrary, the absorption of griseofulvin, an antifun-
gal drug, as well as that of saquinavir, an antiretroviral drug, is increased when taken with a 
“fatty” meal [6, 9, 10].
As depicted in Figure 2, several transportation mechanisms have been envisaged from 
the site of absorption. It should be noted that the preponderance of each transport mech-
anism is different for each individual patient due to their genetic and constitutional 
makeup.
Figure 1. Absorption throughout the gastrointestinal tract. Source: [6].
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3. Systemic concentration and occurrence of adverse effects
The key concept in explaining the effects of drugs is “plasma concentration” or the amount 
of drug that reaches the systematic circulation; it reflects the amount of drug that will be 
available to act and produce effects at the site of action. Classically, it is has been established 
that what is known as the effect of a drug is actually a combination of the action of a drug or 
drug action; its effect or drug effect and the body’s response or drug response. This may be 
illustrated as follows: For example, for a penicillin antibiotic, the “action” consists of inhibit-
ing bacterial protein synthesis, the “effect” corresponds to the killing rate or growth inhibition 
rate of bacteria, and the clinical “response” would be the cure of the body from the infection 
and its manifestations [6, 11, 12].
In order to achieve its effect, a drug must first be released from its pharmaceutical form from 
the site of administration; be absorbed and distributed through the body to reach its site of 
action where it will interact with its specific receptors and/or some other nonspecific recep-
tors. Through its journey, the body acts on it by metabolizing it in order, primarily, to wear 
off and eliminate it. The result of metabolism may sometimes achieve the goal of inactivating 
or destroying the structure of the drug; or sometimes it may lead to the production of active 
metabolites that actually will interact with receptors and produce the expected therapeutic 
effects of the particular drug [11, 13, 14].
For drugs subject the first-pass effect that is drugs that are metabolized before they reach 
the systemic circulation; generally, this pre-systemic metabolism reduces their bioavailabil-
ity except when and if the resulting metabolites are pharmacologically active. In the case of 
nitroglycerin, which is almost totally first metabolized, its di- and mononitrate metabolites 
produced have very much reduced activity, and hence this drug is considered to be inactive 
when taken orally [15].
Figure 2. Transport mechanisms of drugs. Source: [6].
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When a drug successfully crosses the physical and biochemical barriers described above, it 
will reach the systemic circulation and its plasma concentration will continue to rise as for 
as it will be absorbed. If, the increase is beyond a certain threshold, toxic effects or adverse 
effects will be clinically observed. This is well established now that there is an optimum range 
of concentrations over which a drug has beneficial or expected useful effects, with no clinical 
toxicity, this is known as the “therapeutic range,” sometimes referred to as the “therapeutic 
window” [6]. Moreover, it has been established also that there is a threshold concentration 
below which the drug is deemed ineffective, or not producing expected therapeutics effects, 
and a higher threshold above which adverse or unwanted toxic effects become apparent as 
shown in Figure 3.
The plasma concentration fluctuates based on the rates of absorption, the influence of the first-
pass effect, and based on whether the drug is following a one compartment model of distri-
bution or a multiple compartment model. For drugs using the multiple compartment model, 
which are drugs that accumulate in other compartments other than the systemic circulation, 
namely the liver, skeletal muscles, bones, adipose tissues; their absorption, distribution, and 
metabolism may be complex. For instance, thiopental, once absorbed, its liver concentrations 
rapidly equilibrate with those in plasma while the concentrations in skeletal muscle rise ini-
tially and then equilibrate later and their concentrations in adipose tissue will rise for at least 
the first 3.5 h following the bolus injection of thiopental; its duration of action will be short 
due to uptake of the drug into skeletal muscle and fat [16–18].
In order to understand the influence of multiple compartments, it is important to remember 
that typically the body is made of 11 chemical elements, namely carbon, calcium, chlorine, 
hydrogen, nitrogen, magnesium, oxygen, phosphorus, potassium, sodium, and sulfur; and 
5 molecules such as water which comprises 60–62%; proteins 16–18%; fat 10–15%; minerals 
6–7%; up to 1% of carbohydrates [19, 20] (Figure 4).
Figure 3. Drug levels in relation to elicited effects. Source: [6].
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It should be noted that there are variations in the concentration of the elements and mol-
ecules making up the body. These variations are rhythmic, cyclic, and dependent on the age, 
sex, and health status of the individuals. It is known that, in each disease state, and in case 
of multi-morbidity, the composition of these elements and molecules vary in relation to the 
lifestyle of an individual, namely his/her water and food intake, smoking and alcohol con-
sumption, exercise and sleeping patterns in terms of quantity, quality, and variety or diversity 
[21–24]. This situation largely explains why a same dose of a drug may not always produce 
similar effects (beneficial or adverse) on a group of individuals even if they have same body-
weights, are of same ethnicity or sex. This observation explains why standard doses cannot be 
prescribed indiscriminately to each individual patient; hence the new concept of individual-
ized treatment regimen.
The need for individualized regimen can be more understood when one considers the “half-
life” concept. Half-life is a very useful parameter in pharmacokinetics; it is defined as the 
time it takes for the concentration of a drug to halve from its initial peak concentration in 
plasma or urine. It is important to note that even drugs from the same class have different 
half-lives because they have different volumes of distribution and/or systemic clearance. This 
is so because the apparent volume of distribution depends, as said earlier, upon the nature 
of the drug and the makeup of individuals. For instance, lipophilic drugs tend to have large 
apparent volumes of distribution and to be widely distributed in someone who is obese, due 
to the availability of more adipose tissue. Hence, the lipophilic drugs will have a longer elimi-
nation half-life in obese people; their longer stay may mean also longer lingering affects both 
beneficial and unwanted [23, 25, 26].
When drugs accumulating in other compartments continue to be taken, there will be a satura-
tion of the receptors or even storage spaces in these compartments, resulting in much more 
concentrations in the interstitial liquids, and overwhelming of related receptors, thus the 
advent of adverse and side effects not typical of drug class. Such side effects may and should 
become a subject of pharmacovigilance investigation. It should be said here that atypical or 
new side effects may occur even with normal doses in certain individuals because of their 
uniqueness with regard to the receptors, enzymes, or proteins, they may have in abundance 
or absence thereof as a matter of their genetic makeup or as a result of a subclinical or clinical 
Figure 4. Body composition. Source: Fomon et al. [19]; Chumlea et al. [20].
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disease state as well as their lifestyle as already explained. In case of overdose, drug metabo-
lism is altered because enzymes responsible for metabolism become saturated; this leaves 
the excess drug free to force its way to nonspecific receptors by overcoming both inhibition 
or competition; consequently, it produces nontypical adverse effects while its clearance is 
decreased and its half-life is prolonged [27–30].
4. Elimination or excretion of drugs and adverse effects
Once a drug is metabolized and reduced to hydrosoluble entities, it is ready to be excreted 
through the kidneys and eliminated in the urine. However, some changes may impact nega-
tively to this process. An important pharmacokinetic change in the elderly, for instance, is the 
decrease in renal drug elimination due to the fact that as someone ages, his/her renal mass as 
well as glomerular filtration and tubular secretion capacities decrease. It should be noted that 
after age 40, there is a decrease in the number of functional glomeruli, and the renal blood 
flow is estimated to decline by approximately 1% yearly. The clinical effect of decreased renal 
clearance includes prolonged drug half-life, increased serum drug level to toxic level which 
obviously leads to increased potential for adverse drug reactions [6, 31].
5. Pharmacokinetics related risk factors of adverse effects
At the core, genetic factors play a major role because of the genetic polymorphism or differ-
ence in drug responses between individuals. The drug response is genetically determined 
by the type, quality, and quantity of genes, proteins, enzymes that one has. A well-known 
example suffices here, the case of the enzyme, N-acetyltransferase which differs between 
individuals such that the population may be divided into slow and fast acetylators. People 
who are slow acetylators may experience more adverse effects unless doses of drugs requir-
ing acetylation for metabolism are reduced. Other inherited variations in pharmacokinetics 
include deficiency of one or more hepatic cytochrome-P450 isozymes or plasma cholinester-
ase enzymes. The metabolic conversion of drugs into metabolites is established as a source of 
several idiosyncratic drug reactions [32–38].
As stated above, lifestyle factors such as diet and exercise affect bodyweight which is used as 
the basis for determining the dose administered. In case of chronic diseases, an increase or a 
drop of 10–20% in bodyweight should normally be noted and followed by a dose adjustment. 
Tuberculosis treatment is an example whereby patients normally increase their bodyweights 
sometimes up to 30% of their initial weights within 2–4 months. Clearly based on the treat-
ment algorithms as defined by WHO, the doses or number of tablets for these patients should 
increase following the increase in their bodyweights; however, often this is not usually done [39, 
40]. Moreover, diet, smoking, and alcohol may affect enzyme activity and lead to unexpected 
drug interactions. Cigarette smoking affects drug therapy by pharmacokinetic. The polycy-
clic aromatic hydrocarbons in tobacco smoke are believed to be responsible for the induc-
tion of cytochrome P450 (CYP) 1A1 and CYP1A2 which are responsible for the metabolism 
Introductory Chapter: Linkages between Pharmacokinetics and Adverse Effects of Drugs
http://dx.doi.org/10.5772/intechopen.76511
7
of a number of drugs. Drugs for which induced metabolism because of cigarette smoking 
may have clinical consequence include theophylline, caffeine, tacrine, imipramine, haloperi-
dol, pentazocine, propranolol, flecainide, and estradiol. Cigarette smoking results in faster 
clearance of heparin, possibly related to smoking-related activation of thrombosis that results 
in enhanced heparin binding to antithrombin factor III [41, 42]. Moreover, cutaneous vaso-
constriction by nicotine may slow the rate of insulin absorption after subcutaneous admin-
istration. Hence, the impact of cigarette smoking needs to be considered in planning and 
assessing responses to drug therapy; this why clinicians should regularly enquire of smoking 
and drinking habits of their patients [43, 44].
With regard to sex, differences between male and female will include differences in weight 
and weight distribution as well as hormonal differences particularly in relation to the men-
strual cycle and its absence in prepubescent girls and postmenopausal women [45]. Moreover, 
physiological differences relating to body composition, gastric motility, liver metabolism, 
renal function, and glomerular filtration rates all affect differently the disposition of drugs 
with regard to gender. Simply put, drug absorption, distribution, metabolism, and elimina-
tion are not actually similar in men and women. Drug absorption in the lung may differ 
according to gender [46]. It has been demonstrated that there is a significant less deposition of 
an aerosolized drug in women than men which has been ascribed to differences in breathing 
patterns. Gastrointestinal transit time is longer in women (mean 91.7 h) than in men (44.8 h), 
as is gastric emptying time. This situation causes delays in the absorption of certain drugs. 
It has been shown for instance that following oral doses of levofloxacin and losartan, the 
areas under the curve (AUC) of these drugs were significantly greater in females than males. 
Moreover, relatively fast absorption of oral salicylates and that of ferrous sulfate has been 
shown in females and prepubertal girls than in boys. After intravenous infusion, the systemic 
clearance of verapamil was shown to be greater in women than in men. In case of propofol, 
women are said to be less sensitive to the effects of propofol and recover from anesthesia more 
quickly than men. This observation was demonstrated in a study that showed that the AUC 
values for the metabolites, 4-hydroxypropofol and propofol glucuronide, were significantly 
higher in women than in men and that this effect was 3.6 times higher in Hispanic females 
than in Caucasian females. On the contrary, protein binding is reportedly higher in males 
than females, for chlordiazepoxide and warfarin. Hepatic enzyme CYP3A4 is more active in 
females than males; drugs metabolized by this enzyme are thus affected more efficiently in 
females than males [47–50].
With regard to age, in children, their low gastric acid secretion can result in increased serum 
concentrations of weak bases and acid-labile medications, such as penicillin, and decreased 
serum concentrations of weak acid medications, such as phenobarbital, due to increased ion-
ization. Additionally, gastric emptying time and intestinal transit time are delayed in pre-
mature infants; this increases drug contact time with the GI mucosa, hereby increasing drug 
absorption. In neonates, infants, and young children, there is increased risk of ADRs because 
of their incapacity to metabolize most drugs due to lack of appropriate enzymes and related 
functions. For instance, in neonates of less than 2 months old, because of their immature renal 
tubular function, it is recommended to avoid digoxin, aminoglycosides, ACE inhibitors, and 
NSAIDs [11, 51–53].
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In the elderly, it is well known that the incidence of diseases increases with aging. A major 
consideration is the presence of comorbid conditions present in aging people that affect 
plasma concentrations of drugs through changes in the extent of absorption, in the rates of 
metabolism and/or excretion, and changes in tissue localization, for example, increased tis-
sue binding leading to reduced plasma concentrations. In case of warfarin, age was found to 
have a significant effect on dosing; older patients require much lower doses than the young 
adults. Furthermore, it is well established that higher gastric pH, delayed gastric empty-
ing, and decreased intestinal motility and blood flow are observed in elderly individuals. 
Consequently, even normal doses for health adults may become overdosage in the elderly 
patients who may experience more and severe adverse effects. Other factors that affect distri-
bution of drugs in the body are changes in body fat and water and changes in protein binding. 
In the elderly, lean body mass can decrease by as much as 12–19% through the loss of skel-
etal muscle. Thus, blood levels of drugs primarily distributed in muscle such as digoxin will 
increase and become a risk for overdose when normal or standard dose are used. Moreover, 
due to a decrease in water concentration in older people, hydrosoluble drugs would reach 
higher concentrations because there is less water to dilute them while liposoluble drugs 
would accumulate more because there is relatively more fat tissue to store them. Furthermore, 
the kidney and liver functions perform less optimally; hence drugs are not readily metabo-
lized and excreted into the urine to be eliminated. This leads to many drugs staying much 
longer than they do in a younger person’s body, the net result would be the prolongation of 
pharmacodynamic effects and occurrence of side effects [2, 54–63].
With regard to disease states, there are pharmacodynamic differences in patients with liver 
disease. Effects have been observed with β-blockers and drugs that depress the CNS. In case 
of β-blockers, it is documented that there is a reduction in β-adrenoceptor density in mono-
nuclear cells which results in a decrease in effect; this has been observed with propranolol. 
Similarly, patients with liver cirrhosis had been found to be particularly sensitive to opi-
oids and anxiolytics. In case of kidney disease, a drug that is 100% metabolized may also 
be affected to some extent particularly its excretion if its metabolites accumulate in plasma, 
leading to an exaggerated response if the metabolites contribute to the pharmacological effect; 
or, atypical toxicity that is not seen when the metabolites are excreted normally. Additionally, 
renal impairment is likely to lead to varying degrees of water loading and this may lead to 
the changes in the concentrations of the drug in the fluid compartments of the body, includ-
ing plasma. Children with cystic fibrosis present with greater renal clearance of drugs such 
as aminoglycosides when compared with children without the disease; this observation sug-
gests that higher doses by weight and more frequent dosing intervals are required in these 
children [64–72].
With regard to drug-drug interactions, it should be said that patients commonly use two or 
more drugs concurrently; some prescribed by their health care providers, others bought by 
themselves or received from family and friends. Because patients are often unaware of the 
multiple drug interactions, they suffer from adverse drug reactions resulting from alterations 
of the pharmacokinetics parameters due to interacting substances; often with the end result 
being a decreased therapeutic efficacy, or an increased toxicity or occurrence of adverse effects. 
The binding of drugs to macromolecules such as receptors on plasma proteins is governed 
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by the law of mass action which states that “the rate at which a chemical reaction proceeds is 
proportional to the active masses (usually molar concentrations) of the reacting substances.” 
Taken from chemistry point of view, this concept means that for the reaction to occur, colli-
sion between the reacting molecules must take place. It follows that the rate of reaction will be 
proportional to the number of collisions; while the number of collisions will be proportional 
to the molar concentrations of the reacting molecules. Hence, drugs-foods and drugs-drugs 
interactions will affect the rates of a drug disposition based on the quantities available of 
the doses taken and the synchronicity which implies the presence of both substances at the 
same time for them to interact directly or indirectly through competition or inhibition of rel-
evant receptors. The above observations imply that the degree of drug interaction depends on 
the relative concentrations of each drug; hence, the dose and the time of administration are 
critical elements in the onset of adverse effects resulting from drug-drug interactions. These 
interactions may produce changes in absorption rate, competition for binding sites on plasma 
proteins, oral bioavailability, extent and volume of distribution in organs and tissues, and 
hepatic and renal clearance as well as the extent of elimination from the body. Indeed besides 
other medicines, drugs of abuse, herbal medicines, and foodstuffs have been reported to affect 
the pharmacokinetics of specific drugs [73–78].
The above observations suggest the need for caution when prescribing more than one drug as 
well as the need to counsel patients about the dangers of taking nonprescribed drugs, drugs 
for entertainment including alcoholic drinks without seeking proper advice from health care 
professionals [79–84].
6. Concluding remarks
Adverse effects as unwanted outcomes of drugs effects occur generally when the upper 
threshold of therapeutic dosage range is reached. However, several factors may lower this 
threshold or bring about the trespassing of the therapeutic level. Risks factors include intrin-
sic properties of the drugs and the pharmaceutical dosage forms issues and interactions that 
affect their pharmacokinetics as well as the sociodemographic, health status, and lifestyle 
factors superimposed on the genetic makeup of a person. Clinicians ought to understand the 
pharmacokinetics of a drug before deciding to adjust dosages particularly upwardly as a pre-
cautionary measure to preempt dose-related adverse effects. Equally, they should not refrain 
from doing so when the situation warrants it; such as when the bodyweights of patients have 
significantly increased or when pharmacokinetic changes dictate so.
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